The AIM with Immunotherapy Initiative – Home › Forums › Immunotherapy › Side-effect management › pembrolizumab › Reply To: pembrolizumab
October 3, 2017 at 7:02 pm #4191
Expert NurseJane Thompson
Generally, the safety profile of pembrolizumab is similar across tumor types. However, the context may be different—patients with other tumor types may have differing comorbidities or underlying organ dysfunction. For example, lung cancer patients may have underlying lung disease that will exacerbate shortness of breath associated with pneumonitis.